ライフサイエンスコーパス: genetic screening

1 utive ARVC families undergoing comprehensive genetic screening.

2 gene variants identified in long QT syndrome genetic screening.

3 virus (MCMV), as identified through unbiased genetic screening.

4 evelopment in zebrafish has been applied for genetic screening.

5 cells and show their application in forward genetic screening.

6 ibit widespread interactions in genome scale genetic screening.

7 ised an exon hierarchy analysis strategy for genetic screening.

8 for applications in medical diagnostics and genetic screening.

9 rmination of the nonclinical implications of genetic screening.

10 s, are needed to determine the usefulness of genetic screening.

11 lators and downstream targets of caspases by genetic screening.

12 particularly with the application of pooled genetic screening.

13 ferentiation potential and applicability for genetic screening.

14 immune response than pretreatment biopsy or genetic screening.

15 ese cells as a platform for loss-of-function genetic screening.

16 l in next generation chips for bioassays and genetic screening.

17 new strategy for adult disease prevention by genetic screening.

18 atosis that can be readily identified before genetic screening?

19 mportant implications for the development of genetic screening algorithms.

20 red in an age group frequently excluded from genetic screening algorithms.

21 Through targeted disruption and genetic screening, an increasing number of genes have be

22 Identification of the gene will allow genetic screening and a specific diagnosis for a disease

23 mutagenesis expands the toolbox for forward genetic screening and also provides direct evidence that

24 Continued genetic screening and analysis of Arabidopsis mutants ha

25 otype will help clinical diagnosis, targeted genetic screening and appropriate management.

26 nt of exon hierarchy analysis strategies for genetic screening and better understanding and recogniti

27 The integration of forward genetic screening and biochemical profiling opens a path

28 nt integration between the expected yield of genetic screening and cost may allow the formation of cr

29 Prenatal genetic screening and diagnostic testing can identify ma

30 Prenatal genetic screening and diagnostic tests are changing rapi

31 Here, through a combination of genetic screening and directed mutagenesis with the type

32 In this study, we used genetic screening and downstream validation to identify

33 sing both evolutionarily distant species for genetic screening and functional assessment to identify

34 s a common finding in aHUS patients and that genetic screening and functional tests of ADAMTS13 shoul

35 undant collection that is suitable for rapid genetic screening and gene discovery.

36 We use results of forward genetic screening and genetic analysis in our new model

37 the EpRE and interacts with the ER in yeast genetic screening and in vitro assays.

38 8 into 4-thiouridine has been identified by genetic screening and its role in 4-thiouridine generati

39 Through a combination of CRISPR-Cas9-based genetic screening and metabolomic analyses, we show that

40 ms (SNPs) has potential applications in both genetic screening and pharmacogenomics.

41 f experimental approaches, including forward genetic screening and transcriptional profiling of suppo

42 rtant for applications in disease diagnosis, genetic screening, and drug discovery.

43 e natural history, the yield of familial and genetic screening, and the arrhythmogenic mechanisms in

44 o diagnose patients definitively, to perform genetic screening, and to delineate the clinical manifes

45 ellular antibody capture (IAC) is based on a genetic screening approach and is a facile methodology w

46 Here we report a novel, clinically guided genetic screening approach for the identification of onc

47 Here, we describe a pooled, loss-of-function genetic screening approach suitable for both positive an

48 Here we use a pooled in vivo genetic screening approach using CRISPR-Cas9 genome edit

49 The guided genetic screening approach validated by this study offer

50 Using a genetic screening approach, we identify the ubiquitin-sp

51 didate oncogenic drivers of HCC in a forward genetics screening approach.

52 We used two different genetic screening approaches to identify Saccharomyces c

53 of clinical phenotype in guiding individual genetic screening at this time.

54 We used a combination of forward genetic screening based on a Proline Dehydrogenase1 (PDH

55 sible for this progression, we carried out a genetic screening by an enhanced retroviral mutagen (ERM

56 to histopathologic examination and molecular genetic screening by clonotype primer-directed polymeras

57 Rapid genetic screening by restriction enzyme analysis of vira

58 e of interest is frequently achieved through genetic screening by RNA interference (RNAi) or knockout

59 This approach can simplify genetic screening by targeting the gene for initial stud

60 Chemical genetic screening can be described as a discovery approa

61 in general and, in combination with chemical genetic screening, can be used to identify host cell fun

62 The detection of leukemia cells on newborn genetic screening cards ("Guthrie cards") of a small gro

63 t glucose has a role in fly biology and that genetic screenings carried out in flies may increase our

64 The use of molecular genetic screening currently has some legitimacy in certa

65 of the spectrum of disease and refinement of genetic screening, diagnostic tests, and surgical manage

66 have been identified in 71 plant species by genetic screening, direct cloning after isolation of sma

67 also discuss the application of genome-wide genetic screening efforts to gain insight into synthetic

68 Genetic screening efforts with invertebrates have unrave

69 rebrospinal fluid, endocrine, metabolic, and genetic screening findings were normal or negative.

70 Genetic screening for a germline mutation at the RET gen

71 arcoded mutants unlocks the power of reverse genetic screening for a malaria parasite and will enable

72 e lhr1 mutant was isolated through a forward genetic screening for altered expression of the lucifera

73 breast cancer are often counseled to receive genetic screening for BRCA1 and BRCA2 mutations, the str

74 tors, are likely to alter fundamentally both genetic screening for celiac disease and its therapy.

75 6 at-risk subjects undergoing endoscopic and genetic screening for FAP.

76 s for Pro-16, Asp-18, and Asn-19 followed by genetic screening for functional proteins.

77 onent is missing, and (3) the need for rapid genetic screening for gene expression changes in living

78 ntal modifiers, and psychosocial outcomes of genetic screening for hemochromatosis.

79 Research addressing genetic screening for hereditary hemochromatosis remains

80 te the benefit from, widespread or high-risk genetic screening for hereditary hemochromatosis.

81 Limitations: This review considered genetic screening for HFE-related hereditary hemochromat

82 se of hematopoietic stem cells to facilitate genetic screening for malaria host factors.

83 Genetic screening for molecules involved in Shiga toxin

84 Our genetic screening for mutations that resist CLE peptide

85 approaches have hindered systematic forward genetic screening for NMD factors in human cells.

86 Fireworks) that enables CRISPR-based forward genetic screening for NMD pathway defects in human cells

87 nvolving living cells facilitate large-scale genetic screening for novel biological activities.

88 Patients underwent genetic screening for NPM1, FLT3-ITD, FLT3-D835, and CEB

89 This observation instigated further genetic screening for prostacyclin receptor variants on

90 Individual genetic screening for rare high-risk traits or for more

91 uction have already been defined, continuous genetic screening for regulators of innate immunity may

92 challenges faced by families as a result of genetic screening for SADS to enable equitable access to

93 ated gene disruption procedure and performed genetic screening for single P-element insertion mutatio

94 The assay allows simple, high throughput genetic screening for these common hematological disorde

95 is important for basic and medical research; genetic screening for those genes in Caenorhabditis eleg

96 Clinical and genetic screening for VHL in this family had a significa

97 The diffusion and availability of genetic screening gave a new relevance to the applicatio

98 Reverse genetic screening has been highly useful for determinati

99 Genetic screening has reduced the incidence of untreatab

100 n the coding sequence or by splice variants, genetic screening has revealed a large number of missens

101 Genetic screening has shed light on the molecular mechan

102 rs; however, routine guidelines for clinical genetic screening have been established only in the form

103 Genetic screening identified an A896T substitution in a

104 Genetic screening identified the gene sma0113 as needed

105 Genetic screening identifies the atypical tetraspanin TM

106 Genetic screening identifies zebrafish mutants, such as

107 These findings may help direct genetic screening in a busy neurology outpatient setting

108 Genetic screening in both cases shows the heterozygous R

109 Through genetic screening in C. elegans, we uncover two metformi

110 Thus, genetic screening in Drosophila can be successfully appl

111 Using genetic screening in Drosophila, we have identified Fasc

112 erence (RNAi) has become a powerful tool for genetic screening in Drosophila.

113 in the Dominican Republic, that could guide genetic screening in each location.

114 We used the power of genetic screening in human cells and found that RVFV uti

115 oxicity mechanism, made possible by unbiased genetic screening in human cells, suggests that the sele

116 interference (RNAi) for its potential use in genetic screening in mice.

117 emonstrate the feasibility of using RNAi for genetic screening in mice.

118 In vitro mutational and genetic screening in Salmonella enterica serovar Typhimu

119 r causative mutations in INCL and facilitate genetic screening in selected high-risk populations.

120 is enterprise has been joined by large-scale genetic screening in the zebrafish, where a number of in

121 ecently described a yeast assay suitable for genetic screening in which simple religation nonhomologo

122 e address this need by using high-throughput genetic screening in yeast to select variants of the iro

123 We used forward genetic screening in zebrafish to test the hypothesis th

124 f haploid cell lines has facilitated forward genetic screenings in mammalian cells.

125 Transposon-mediated forward genetics screening in mice has emerged as a powerful too

126 entiviral short hairpin RNA (shRNA)-mediated genetic screening is a powerful tool for identifying los

127 Haploid genetic screening is a powerful tool to reveal factors i

128 Genetic screening is becoming possible on an unprecedent

129 It is unknown whether genetic screening is indicated in the general population

130 Genetic screening is not necessary to diagnose or initia

131 While locomotor-based behavioral genetic screening is successful in identifying genes in

132 Genetic screening is the most powerful method through wh

133 Routine genetic screening is unlikely until management is improv

134 pel-Lindau (VHL) disease in whom clinical or genetic screening led to the detection of surgically res

135 Preoperative genetic screening may guide intraoperative management to

136 with a high prevalence of BRCA1/2 mutations, genetic screening may significantly increase average sur

137 Here, we use a combination of genetic screening, MD simulations, and biochemical and m

138 e have developed a novel retrovirus-mediated genetic screening method in cultured cells.

139 To achieve this goal, we used a new genetic screening method using enhanced retroviral mutag

140 Here we present a genetic screening method using photo-highlighting for ca

141 To overcome this limitation, a novel genetic screening method was devised to convert type IIS

142 We used a genetic screening methodology, a human cell line bearing

143 decades to achieve with conventional forward genetic screening methods and mammalian cell cultures.

144 f gene expression can complement traditional genetic screening methods for the identification of gene

145 Using differential genetic screening methods, we show that defective KSHV i

146 a parasites is hampered by a lack of reverse genetic screening methods.

147 ble for traits difficult to analyze by other genetic screening methods.

148 A (allene oxide synthase, AOS) using reverse genetics screening methods.

149 the planarian flatworm as a simple chemical-genetic screening model for nervous system regeneration

150 Genetic screening of 133 unaffected Hungarian Vizslas re

151 Genetic screening of 171 patients with frontotemporal lo

152 Forward-genetic screening of 3237 R(1) lines resulted in identif

153 Finally, genetic screening of 44 patients revealed >/=2 ABCA4 mut

154 Genetic screening of a further 367 isolated dystonia sub

155 We recommend that genetic screening of aHUS includes analysis of CFH and C

156 Genetic screening of an E. coli genomic library was perf

157 In this study, a genetic screening of an E. coli genomic library was perf

158 lies of CCHS probands with PHOX2B mutations, genetic screening of appropriate family members is indic

159 zygous for the C282Y mutation ascertained by genetic screening of blood donors; and patients presenti

160 efore, serve as a useful diagnostic tool for genetic screening of certain syndromic ciliary diseases.

161 Recently, genome-wide genetic screening of common DNA sequence variants has pr

162 ese results support the use of comprehensive genetic screening of desmosomal genes for arrhythmic ris

163 Through genetic screening of dilated cardiomyopathy patients, we

164 Routine genetic screening of HCM patients for specific mutations

165 nistration of potentially toxic 5-FU and for genetic screening of heterozygous carriers and homozygou

166 frequency impact variant categorization for genetic screening of nonsyndromic hearing loss (NSHL) an

167 Following genetic screening of Parkinson's disease patients and he

168 Genetic screening of patients diagnosed with macular dys

169 Interestingly, genetic screening of patients with dilated cardiomyopath

170 2012, the authors have included FLNC in the genetic screening of patients with inherited cardiomyopa

171 To maximize clinical benefits of genetic screening of patients with nephrotic syndrome (N

172 through characterization of mutant mice and genetic screening of patients.

173 In treatment decisions, genetic screening of related donors for hematopoietic st

174 known MeCP2 isoform has implications for the genetic screening of Rett syndrome patients and for stud

175 Genetic screening of symptomatic patients or asymptomati

176 ses a MELAS-like phenotype, and suggests the genetic screening of the MRM2 gene in patients with a m.

177 Based on genetic screening of this model, we identified three RNA

178 Our model suggests that genetic screening of this population could prolong avera

179 Altogether, this and previous genetic screening of yeast led to the identification of

180 plexed CRISPR/Cas9 can be used for recessive genetic screening or high-throughput cancer gene validat

181 s are coded by a family of genes, precluding genetic screening or nuclear transformation approaches f

182 Here, we describe a forward genetic screening paradigm exploiting CRISPR-mediated ge

183 In our genetic screening, Pink1 and Park genes were identified

184 pan assays limit their usefulness as a broad genetic screening platform for research on aging.

185 A high-throughput genetic screening platform in a single-celled photosynth

186 For these reasons, comprehensive genetic screening platforms have been developed with the

187 gm with significant potential for developing genetic screening platforms in mammalian cells.

188 The mutants were isolated using a genetic screening procedure which eliminates mutations t

189 The pedigree is the first step in the genetic screening process and can guide the clinician in

190 who were consecutively identified through a genetic screening program as carriers of a RET mutation

191 Genetic screening programs in unselected individuals wit

192 Our work shows that forward genetic screening provides a powerful route to identify

193 preclinical tool for drug testing and large genetic screening relevant to the study of executive dys

194 Our re-analysis of a previous genetic screening result in Caenorhabditis elegans shows

195 l ordering and correct interpretation of the genetic screening results.

196 domonas reinhardtii, previously recovered by genetic screening, results from a leucine 290 to phenyla

197 Our genetic screening revealed varying mutation frequencies

198 Surprisingly, genetic screening reveals that yeast FTase can modify se

199 This forward genetic screening scheme is useful and applicable to any

200 Extensive genetic screening should become a standard procedure to

201 er strategy has come to be known as "cascade genetic screening." Since the carrier risk of close rela

202 esults demonstrate the power of our chemical-genetic screening strategies for pinpointing the physiol

203 In this study, we describe a genetic screening strategy and demonstrate its use in sc

204 We developed a versatile, high-throughput genetic screening strategy by coupling gene mutagenesis

205 We developed a genetic screening strategy called insertional mutagenesi

206 tional mutagenesis and depletion (iMAD) is a genetic screening strategy for dissecting complex intera

207 hat CRISPR can be used as a powerful reverse genetic screening strategy in vivo in a vertebrate syste

208 Based on yeast growth rescue, we present a genetic screening strategy that identified RACK1 as an E

209 Here we describe a genetic screening strategy to isolate fertilization muta

210 Broad application of this highly parallel genetic screening strategy will not only facilitate the

211 should be adopted in future mechanistic and genetic screening studies.

212 The recent genetic screening study in Caenorhabditis elegans has li

213 Genetic screening study of the MTATP6 gene in 64 pedigre

214 Genetic screening, such as that used most frequently for

215 Forward genetic screening suggests that multiple receptors are i

216 Using a yeast genetic screening system, we identify Lhx3 point mutants

217 g engineered transposons is a potent forward genetic screening technique used to identify cancer gene

218 In addition, use of a genetic screening test raises concerns regarding possibl

219 search and clinical laboratories as low cost genetic screening tests.

220 here is a need for practical, cost-efficient genetic screening tests.

221 Here, we report the design of a genetic screening that uncovered Dma1 as another E3 liga

222 nd mice are suitable for pharmacological and genetic screening to detect effects on expression of LDL

223 Our studies demonstrate the power of genetic screening to discover cancer drivers that are di

224 substitutions at this position were found in genetic screening to exhibit a dominant lethal phenotype

225 s in this group highlights the importance of genetic screening to identify abnormalities that may be

226 the first application of such a large-scale genetic screening to vertebrate development.

227 ages of FO-SPR as a high resolution and fast genetic screening tool that can compete with the current

228 As CRISPR-Cas is a relatively new genetic screening tool, it is important to assess its fu

229 o observed that although not detected in our genetic screening, two cold shock-inducible proteins, na

230 Following genetic screening using a shade-responsive luciferase re

231 hat improves the efficiency of combinatorial genetic screening using an effective strategy for clonin

232 Combinatorial genetic screening using CRISPR-Cas9 is a useful approach

233 Genetic screening using flagellin mutants of L. pneumoph

234 complementary approach, we discuss parallel genetic screening using next-generation sequencing follo

235 Genetic screening using random transposon insertions has

236 seful for high-throughput pharmacological or genetic screening using rodent models.

237 creening using enhancer trapping and forward genetic screening using transposon insertional mutagenes

238 The yield of genetic screening was low (14%), despite familial diseas

239 Through a chemical genetic screening, we have identified a small molecule,

240 , from a cell-based high-throughput chemical genetic screening, we identified a small molecule SC79 t

241 Using chemical genetic screening, we tested a library of known phosphat

242 ulators and their cellular targets, chemical genetic screenings were performed with triazine-based co

243 esults also pave the way for high-throughput genetic screening with CRISPR/Cas.